Who
Foundation Fighting Blindness Retinal Degeneration Fund
Director and Other role
Company insider
Files Form 4 as: Director and Other, Opus Genetics.
In numbers
- Trades disclosed
- 4
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $26.1M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 9 Dec 2025
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $2.8M556,000 at $4.96 | filing |
| 18 May 2026filed 20 May 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $7.4M1,700,000 at $4.35 | filing |
| 18 May 2026filed 20 May 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $7.4M1,700,000 at $4.35 | filing |
| 9 Dec 2025filed 11 Dec 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $8.6M4,000,000 at $2.15 | filing |
News
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessIRD · manilatimes.net · 21 Oct 2026Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Foundation Fighting Blindness Retinal Degeneration Fund; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.